Last10K.com

Arch Therapeutics, Inc. (ARTH) SEC Filing 10-Q Quarterly report for the period ending Thursday, December 31, 2020

SEC Filings

ARTH Registration of Securities

Arch Therapeutics, Inc.

CIK: 1537561 Ticker: ARTH
Document And Entity Information - shares
3 Months Ended
Dec. 31, 2020
Feb. 11, 2021
Document And Entity Information  
Document Type10-Q 
Amendment Flagfalse 
Document Period End DateDec. 31, 2020 
Document Fiscal Year Focus2021 
Document Fiscal Period FocusQ1 
Entity Registrant NameArch Therapeutics, Inc. 
Title of 12(g) SecurityCommon Stock, par value $0.001 per share 
Entity Central Index Key0001537561 
Current Fiscal Year End Date--09-30 
Entity Current Reporting StatusYes 
Entity Filer CategoryNon-accelerated Filer 
Trading SymbolARTH 
Entity Common Stock, Shares Outstanding 193,594,766
Entity Shell Companyfalse 
Entity Emerging Growth Companyfalse 
Entity Small Businesstrue 
Entity Interactive Data CurrentYes 

View differences made from one quarter to another to evaluate Arch Therapeutics, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Arch Therapeutics, Inc..

Continue

Assess how Arch Therapeutics, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Arch Therapeutics, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2021 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Financial Statements, Disclosures and Schedules

Inside this 10-Q Quarterly Report

Document And Entity Information
Consolidated Balance Sheets
Consolidated Balance Sheets (Parenthetical)
Consolidated Statements Of Cash Flows
Consolidated Statements Of Changes In Stockholders' (Deficit)
Consolidated Statements Of Operations
2015 Private Placement Financing
2015 Private Placement Financing - Additional Information (Details)
2016 Private Placement Financing
2016 Private Placement Financing - Additional Information (Details)
2017 Registered Direct Offering
2017 Registered Direct Offering (Tables)
2017 Registered Direct Offering - Additional Information (Details)
2017 Registered Direct Offering - Derivative Liabilities Using Black Scholes Model (Details)
2017 Registered Direct Offering - Fair Value Of Derivative (Details)
2018 Registered Direct Offering
2018 Registered Direct Offering (Tables)
2018 Registered Direct Offering - Additional Information (Details)
2018 Registered Direct Offering - Derivative Liabilities Using Black Scholes Model (Details)
2018 Registered Direct Offering - Fair Value Of Derivative (Details)
2019 Registered Direct Offering
2019 Registered Direct Offering (Tables)
2019 Registered Direct Offering - Additional Information (Details)
2019 Registered Direct Offering - Derivative Liabilities Using Black Scholes Model (Details)
2019 Registered Direct Offering - Fair Value Of Derivative (Details)
Basis Of Presentation And Description Of Business
Inventories
Inventories (Details)
Inventories (Tables)
October 2019 Registered Direct Offering
October 2019 Registered Direct Offering (Details)
Payroll Protection Program Loan
Payroll Protection Program Loan (Details)
Property And Equipment
Property And Equipment (Details)
Property And Equipment (Tables)
Property And Equipment - Additional Information (Details)
Risks And Uncertainties - Covid-19
Series 1 Convertible Notes
Series 1 Convertible Notes (Details)
Series 2 Convertible Notes
Series 2 Convertible Notes (Details)
Stock-Based Compensation
Stock-Based Compensation (Tables)
Stock-Based Compensation - Additional Information (Details)
Stock-Based Compensation - Restricted Stock Activity (Details)
Stock-Based Compensation - Stock Compensation Activity (Details)
Stock-Based Compensation - Weighted Average Restricted Stock (Details)
Subsequent Events
Subsequent Events (Details)
Summary Of Significant Accounting Policies
Summary Of Significant Accounting Policies (Details)
Summary Of Significant Accounting Policies (Policies)

Material Contracts, Statements, Certifications & more

Arch Therapeutics, Inc. provided additional information to their SEC Filing as exhibits

Ticker: ARTH
CIK: 1537561
Form Type: 10-Q Quarterly Report
Accession Number: 0001104659-21-021968
Submitted to the SEC: Fri Feb 12 2021 4:25:13 PM EST
Accepted by the SEC: Fri Feb 12 2021
Period: Thursday, December 31, 2020
Industry: Surgical And Medical Instruments And Apparatus

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/arth/0001104659-21-021968.htm